CAS 852155-81-8

Fórmula: C20H31N7O9

InChI: InChI=1S/C20H31N7O9/c1-9(25-18(33)12(21)5-11-6-22-8-24-11)17(32)26-13(3-4-15(30)31)19(34)23-7-14(29)27-16(10(2)28)20(35)36/h6,8-10,12-13,16,28H,3-5,7,21H2,1-2H3,(H,22,24)(H,23,34)(H,25,33)(H,26,32)(H,27,29)(H,30,31)(H,35,36)/t9-,10+,12-,13-,16-/m0/s1

Clave InChI: LUWRDKLVTXFZFK-AWCHJOLGSA-N

SMILES: C[C@H]([C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC1=CN=CN1)N)O

HAEGT

CAS: 852155-81-8

HAEGT

Fórmula: C₂₀H₃₁N₇O₉

Pureza: 98%

Peso molecular: 513.5

Ref: 54-OR1134048

HAEGT

CAS: 852155-81-8

Pureza: 98%

Ref: IN-DA01EO3K

HAEGT

CAS: 852155-81-8

HAEGT is the first N-terminal 1-5 residues of GLP-1 peptide.

Fórmula: C₂₀H₃₁N₇O₉

Pureza: 98%

Forma y color: Solid

Peso molecular: 513.5

Ref: TM-TP1381

(4S)-4-[(2S)-2-[(2S)-2-Amino-3-(1H-imidazol-4-yl)propanamido]propanamido]-4-[({[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl}methyl)c arbamoyl]butanoic acid

CAS: 852155-81-8

(4S)-4-[(2S)-2-[(2S)-2-Amino-3-(1H-imidazol-4-yl)propanamido]propanamido]-4-[({[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl}methyl) c arbamoyl]butanoic acid is a glp-1 analogue that may be used for the treatment of metabolic disorders. It has been shown to increase insulin production in response to glucose and also has site specific activity. The compound binds to insulin receptors, which leads to increased synthesis of intracellular insulin and activation of downstream signaling pathways. The analog has a neutral pH and is stable in biological fluids such as human serum or dogfish plasma.

Fórmula: C₂₀H₃₁N₇O₉

Pureza: Min. 95%

Peso molecular: 513.5 g/mol

Ref: 3D-CJB15581